BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/11/2021 11:07:20 AM | Browse: 788 | Download: 1840
 |
Received |
|
2020-12-21 15:28 |
|
Peer-Review Started |
|
2020-12-21 15:30 |
|
First Decision by Editorial Office Director |
|
2021-01-17 06:10 |
|
Return for Revision |
|
2021-01-17 06:10 |
|
Revised |
|
2021-01-25 14:32 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-03-15 12:59 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-03-16 04:19 |
|
Articles in Press |
|
2021-03-16 04:19 |
|
Edit the Manuscript by Language Editor |
|
2021-03-23 22:42 |
|
Typeset the Manuscript |
|
2021-04-12 14:21 |
|
Publish the Manuscript Online |
|
2021-05-11 11:07 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Case Report |
| Article Title |
Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Min Fei, Xiang-Qiong Wen, Zhao-Lan Yu, Ting Kang, Wei-Hua Wu and San-Tao Ou |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
San-Tao Ou, MD, PhD, Chief Doctor, Professor, Department of Nephrology, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. ousantao@163.com |
| Key Words |
Chronic kidney disease; Renal anemia; Erythropoiesis-stimulating agents; Erythropoiesis-stimulating agent resistance; Roxadustat; Case report |
| Core Tip |
Anemia is a common complication of chronic kidney disease, often in combination with increased morbidity and mortality. Treatment of anemia in advanced chronic kidney disease includes iron replacement and administration of erythropoiesis-stimulating agents (ESAs). However, anemia remains undertreated because of concerns about the safety of ESAs. Roxadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) that stimulates erythropoiesis and regulates iron metabolism. We present a case in which Roxadustat was used for the treatment of a blood transfusion-dependent maintenance hemodialysis patient. This case highlights that increasing HIF activity with small-molecule HIF-PHIs such as Roxadustat is an innovative therapeutic approach for anemia. |
| Publish Date |
2021-05-11 11:07 |
| Citation |
Fei M, Wen XQ, Yu ZL, Kang T, Wu WH, Ou ST. Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature. World J Clin Cases 2021; 9(15): 3680-3688 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i15/3680.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i15.3680 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
